These press releases are for business and financial media.
-
-
- Press release archive 2008
- 08 December 2008
- AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration to Develop and Commercialise Dapagliflozin in Japan AstraZeneca and Bristol-Myers Squibb today announced expansion of their worldwide collaboration to include the development and commercialisation of dapagliflozin in Japan. Dapagliflozin, one of two investigational drugs under joint development by the companies, is currently being studied in Phase III clinical trials in several countries, including the U.S., to assess its efficacy and safety as a once-daily treatment for type 2 diabetes.
-
-
-
- Press release archive 2008
- 03 December 2008
- PN 400 Phase III Studies Show Clinically Meaningful Benefit in Reducing Gastric Ulcers Compared to Enteric-Coated Naproxen AstraZeneca and POZEN Inc., co-development partner for the investigational compound PN 400, have announced today results from two Phase III studies, PN 400-301 and PN 400-302 comparing PN 400 (enteric-coated naproxen 500 mg and immediate release esomeprazole 20 mg) to enteric-coated naproxen 500 mg. These studies were conducted by POZEN under an agreed Special Protocol Assessment (SPA) with the FDA.
-
-
-
- Press release archive 2008
- 28 November 2008
- MedImmune Receives FDA Complete Response Letter on Motavizumab AstraZeneca today announced that MedImmune, its wholly owned biologics business, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) asking for additional information on motavizumab. The CRL is in connection with the Biologics License Application (BLA) for motavizumab for the prevention of serious respiratory syncytial virus (RSV) disease, which was submitted on 30 January 2008. Motavizumab is an investigational monoclonal antibody (MAb).
-
-
-
- Press release archive 2008
- 25 November 2008
- AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva AstraZeneca today announced it has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceuticals USA.
-
-
-
- Press release archive 2008
- 25 November 2008
- AstraZeneca Provides Update on Agreement with Abraxis Biosciences for Co-Promotion of Abraxane in the US On 19 November 2008, AstraZeneca entered into an agreement with Abraxis BioScience, LLC, under which, subject to the satisfaction of terms and conditions thereof, Abraxis would re-acquire exclusive rights to market ABRAXANE in the United States.
-
-
-
- Press release archive 2008
- 20 November 2008
- AstraZeneca to divest Nordic over-the-counter portfolio AstraZeneca today announced the divestment to GlaxoSmithKline of a portfolio of over-the-counter (OTC) products predominantly sold in Sweden. The decision reinforces AstraZeneca’s strategy to focus on innovation in prescription medicines.
-
-
-
- Press release archive 2008
- 20 November 2008
- AstraZeneca to Realign Supply Chain to Improve Productivity and Move Closer to Customers AstraZeneca has today announced proposed changes to its global manufacturing and supply chain operations as part of its ongoing programme to improve efficiency across the business. The introduction of new manufacturing processes has brought further opportunities to drive efficiencies across the global supply chain. The company will also establish a regional packing strategy, to improve its ability to respond to customer requirements, while equipping the business for emerging markets growth.
-
-
-
- Press release archive 2008
- 20 November 2008
- AstraZeneca granted Temporary Restraining Order in PULMICORT RESPULES patent litigation On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva’s budesonide inhalation suspension product, a generic version of AstraZeneca’s PULMICORT RESPULES treatment.
-
-
-
- Press release archive 2008
- 13 November 2008
- SEROQUEL XR and SEROQUEL Approved in Europe for New Indications for the Treatment of Bipolar Disorder AstraZeneca today announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Recognition Procedure (MRP) for new indications in bipolar disorder. SEROQUEL XR and SEROQUEL have been approved for the treatment of major depressive episodes in bipolar disorder. Additionally, SEROQUEL XR has been licensed for moderate to severe manic episodes in bipolar disorder.
-
-
-
- Press release archive 2008
- 09 November 2008
- CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study New data from the JUPITER study demonstrated that CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
-
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 08:15 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
